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The recent WHO Global Policy Report on the Prevention and Control of Viral Hepatitis included data from a survey sent to all nations, to which 126 countries (64.9%) responded. Responding countries varied from 47.4% in the WHO-AFRO region to 100% in the WHO South-East Asia region. This included a spectrum of resource-replete and resource-poor countries. This survey revealed that of the responding countries, only 50.8% had clinical treatment guidelines for HBV and only 62.7% have publicly-funded HBV treatment available. A total of 81.7% have at least one HBV medication on their essential medicines list. However, it must be noted that tenofovir and entecavir, the two most effective nucleoside analogs with lowest barrier of resistance which are now recommended as first-line therapy, 1 were only available in 48. 4 This staggering lack of accessibility to affordable, effective HBV treatments, despite availability of some of these agents for treatment of HIV, needs urgent amendment if any gains are to be made in preventing and controlling the burgeoning global HBV epidemic.
In 2010, the World Health Assembly (WHA) passed a resolution calling for public health intervention to prevent and control viral hepatitis. There is also a forthcoming WHA resolution, requesting the Global Health Fund to provide antiviral medications for HBV mono-infected patients. HBV treatment that is accessible and affordable to all is urgently needed. However, far greater pressure from the international medical community is required to build momentum to move political will and enhance support from the pharmaceutical industry. A concerted effort from international medical associations for liver disease and infectious diseases coupled with community hepatitis groups and healthcare workers is needed to educate and promote viral hepatitis among all levels of the global community. Only through working together, we will build international support for further vital research in viral hepatitis to inform governments and pharmaceutical companies, and help to enforce policy change.
